Sarepta Therapeutics, Inc. (SRPT) Financials
SRPT Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2024-03-31 | 3.2 billion | 2.3 billion |
2023-12-31 | 3.3 billion | 2.4 billion |
2023-09-30 | 3.1 billion | 2.3 billion |
2023-06-30 | 3.1 billion | 2.4 billion |
SRPT Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2024-03-31 | -274.5 million | 40.7 million |
2023-12-31 | -73.7 million | 45.8 million |
2023-09-30 | -155.6 million | 48.1 million |
2023-06-30 | -140.1 million | 47.4 million |
SRPT Net Income
No data available :(
SRPT Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2024-03-31 | 1.4 billion | - | 140.1 million |
2023-12-31 | 1.7 billion | - | 158.8 million |
2023-09-30 | 1.7 billion | - | 134.8 million |
2023-06-30 | 1.9 billion | - | 129.2 million |
SRPT Shares Outstanding
SRPT Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2024-03-31 | 32.4 million | 194.4 million | 127.0 million | - |
2023-12-31 | 19.0 million | 195.5 million | 350.2 million | 218.5 million |
2023-09-30 | 40.9 million | 194.3 million | 120.9 million | - |
2023-06-30 | 17.9 million | 241.9 million | 118.6 million | - |
SRPT Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2024-03-31 | 413.5 million | 50.6 million |
2023-12-31 | 396.8 million | 44.2 million |
2023-09-30 | 331.8 million | 37.0 million |
2023-06-30 | 261.2 million | 34.1 million |
SRPT
Price: $135.43
52 week price:
Payout Ratio Range:
Earnings Per Share: -5.80 USD
P/E Ratio: -15.83
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 366531
Ebitda: -43.3 millionMarket Capitalization: 12.6 billion